Baljinder Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Baljinder Singh has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Deepa Nakmode
Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, Australia
1 shared publication - Haripriya Koppisetti
Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, Australia
1 shared publication Navjot Sandhu
Department of Quality Assurance, ISF College of Pharmacy, Moga, Affiliated to IK Gujral Punjab Technical University, Jalandhar, India
1 shared publicationSanchit Arora
Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India
1 shared publication- Sanjay Garg
Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, Australia
1 shared publication - Weranga Rajapaksha
Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, Australia
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 332
PLGA-Phospholipid Hybrid Oleogel In Situ Forming Implant for Sustained 30-Day Co-Delivery of Donepezil and Memantine
- 22 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 332
Open AccessPLGA-Phospholipid Hybrid Oleogel In Situ Forming Implant for Sustained 30-Day Co-Delivery of Donepezil and Memantine
- 27 June 2023
- Published by Taylor & Francis in Infectious Diseases
- Vol. 55 (10) , 653-663
Emerging trends and insights in acute flaccid myelitis: a comprehensive review of neurologic manifestations
Acute Flaccid Myelitis (AFM) is a neurological condition in the anterior portion of the spinal cord and can be characterised as paraplegia (paralysis of the lower limbs), and cranial nerve dysfunction. These lesions are caused by the infection due to Enterovirus 68 (EV-D68); a member of the Enterovirus (EV) family belongs to the Enterovirus species within the Picornavirus family and a Polio-like virus. In many cases, the facial, axial, bulbar, respiratory, and extraocular muscles were affected, hence reducing the overall quality of the patient's life. Moreover, severe pathological conditions demand hospitalisation and can cause mortality in a few cases. The data from previous case studies and literature suggest that the prevalence is high in paediatric patients, but careful clinical assessment and management can decrease the risk of mortality and paraplegia. Moreover, the clinical and laboratory diagnosis can be performed by Magnetic resonance imaging (MRI) of the spinal cord followed by Reverse transcription polymerase chain reaction (rRT-PCR) and VP1 seminested PCR assay of the cerebrospinal fluid (CSF), stool, and serum samples can reveal the disease condition to an extent. The primary measure to control the outbreak is social distancing as advised by public health administrations, but more effective ways are yet to discover. Nonetheless, vaccines in the form of the whole virus, live attenuated, sub-viral particles, and DNA vaccines can be an excellent choice to treat these conditions. The review discusses a variety of topics, such as epidemiology, pathophysiology, diagnosis/clinical features, hospitalisation/mortality, management/treatment, and potential future developments.
- 27 June 2023
- Published by Taylor & Francis in Infectious Diseases
- Vol. 55 (10) , 653-663
Emerging trends and insights in acute flaccid myelitis: a comprehensive review of neurologic manifestations
Acute Flaccid Myelitis (AFM) is a neurological condition in the anterior portion of the spinal cord and can be characterised as paraplegia (paralysis of the lower limbs), and cranial nerve dysfunction. These lesions are caused by the infection due to Enterovirus 68 (EV-D68); a member of the Enterovirus (EV) family belongs to the Enterovirus species within the Picornavirus family and a Polio-like virus. In many cases, the facial, axial, bulbar, respiratory, and extraocular muscles were affected, hence reducing the overall quality of the patient's life. Moreover, severe pathological conditions demand hospitalisation and can cause mortality in a few cases. The data from previous case studies and literature suggest that the prevalence is high in paediatric patients, but careful clinical assessment and management can decrease the risk of mortality and paraplegia. Moreover, the clinical and laboratory diagnosis can be performed by Magnetic resonance imaging (MRI) of the spinal cord followed by Reverse transcription polymerase chain reaction (rRT-PCR) and VP1 seminested PCR assay of the cerebrospinal fluid (CSF), stool, and serum samples can reveal the disease condition to an extent. The primary measure to control the outbreak is social distancing as advised by public health administrations, but more effective ways are yet to discover. Nonetheless, vaccines in the form of the whole virus, live attenuated, sub-viral particles, and DNA vaccines can be an excellent choice to treat these conditions. The review discusses a variety of topics, such as epidemiology, pathophysiology, diagnosis/clinical features, hospitalisation/mortality, management/treatment, and potential future developments.
- 22 April 2022
- Published by Elsevier in Current Molecular Pharmacology
- Vol. 16 (3) , 243-253
Bedaquiline in Drug-Resistant Tuberculosis: A Mini-Review
Mycobacterium tuberculosis causes a contagious pulmonary disease with a high mortality rate in developing countries. However, the recommendation of DOTS (approved by WHO) was effective in treating tuberculosis, but nowadays resistance from the first line (MDR-TB) and the second line (XDR-TB) drugs is highly common. Whereas, the resistance is a result of factors like poor patient constancy due to the long duration of therapy and co-infection with HIV. The approval of bedaquiline under an accelerated program for the treatment of MDR-TB had revealed its effectiveness in clinical trials as a therapeutic novel molecule. BDQ selectively inhibits the ATP synthase of bacterium and reduces ATP production. Additionally, the poor pharmacokinetic properties had raised provocations in the MDR therapy, but the use of targeted drug delivery can solve the hurdles. While the preclinical and clinical studies included in this review are strongly suggesting the usefulness of BDQ in MDR-TB and XDR-TB, the repurposing of different drug classes in resistant TB is opening new opportunities to manage the disease conditions. In this review, we have summarized the examples of pipeline drugs and repurposed molecules with preclinical formulation developments.
- 22 April 2022
- Published by Elsevier in Current Molecular Pharmacology
- Vol. 16 (3) , 243-253
Bedaquiline in Drug-Resistant Tuberculosis: A Mini-Review
Mycobacterium tuberculosis causes a contagious pulmonary disease with a high mortality rate in developing countries. However, the recommendation of DOTS (approved by WHO) was effective in treating tuberculosis, but nowadays resistance from the first line (MDR-TB) and the second line (XDR-TB) drugs is highly common. Whereas, the resistance is a result of factors like poor patient constancy due to the long duration of therapy and co-infection with HIV. The approval of bedaquiline under an accelerated program for the treatment of MDR-TB had revealed its effectiveness in clinical trials as a therapeutic novel molecule. BDQ selectively inhibits the ATP synthase of bacterium and reduces ATP production. Additionally, the poor pharmacokinetic properties had raised provocations in the MDR therapy, but the use of targeted drug delivery can solve the hurdles. While the preclinical and clinical studies included in this review are strongly suggesting the usefulness of BDQ in MDR-TB and XDR-TB, the repurposing of different drug classes in resistant TB is opening new opportunities to manage the disease conditions. In this review, we have summarized the examples of pipeline drugs and repurposed molecules with preclinical formulation developments.